Needham analyst Gil Blum maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $84.00.
Gil Blum has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s strong position in the current market environment. One of the key reasons is the company’s minimal exposure to tariffs, which shields it from some of the economic challenges that other biotech firms might face. Additionally, Crispr’s substantial cash reserves provide a buffer against the high interest rates that are affecting the industry, allowing the company to maintain financial stability.
Another factor contributing to the Buy rating is the limited competition from China, which is primarily focused on biologics and less advanced modalities, thus not posing a significant threat to Crispr’s market position. Furthermore, despite recent personnel changes at the FDA, Crispr continues to receive support for its cell and gene therapy initiatives, with no immediate regulatory submissions that could introduce high risks. These elements collectively suggest a favorable outlook for Crispr Therapeutics AG, justifying the Buy recommendation.
In another report released on March 25, BMO Capital also maintained a Buy rating on the stock with a $97.00 price target.